KR20180054600A - 면역치료에서의 대식세포 키메라 항원 수용체(moto-car) - Google Patents
면역치료에서의 대식세포 키메라 항원 수용체(moto-car) Download PDFInfo
- Publication number
- KR20180054600A KR20180054600A KR1020187007097A KR20187007097A KR20180054600A KR 20180054600 A KR20180054600 A KR 20180054600A KR 1020187007097 A KR1020187007097 A KR 1020187007097A KR 20187007097 A KR20187007097 A KR 20187007097A KR 20180054600 A KR20180054600 A KR 20180054600A
- Authority
- KR
- South Korea
- Prior art keywords
- tumor
- macrophage
- macrophages
- cell
- scfv
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 175
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 58
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 174
- 108010036901 thymidine kinase 1 Proteins 0.000 claims abstract description 99
- 102100034838 Thymidine kinase, cytosolic Human genes 0.000 claims abstract description 93
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims abstract description 80
- 201000011510 cancer Diseases 0.000 claims abstract description 72
- 102000002689 Toll-like receptor Human genes 0.000 claims abstract description 19
- 108020000411 Toll-like receptor Proteins 0.000 claims abstract description 19
- 210000002865 immune cell Anatomy 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims abstract description 11
- 239000012634 fragment Substances 0.000 claims abstract description 10
- 230000019491 signal transduction Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 80
- 239000000427 antigen Substances 0.000 claims description 48
- 102000036639 antigens Human genes 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 48
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 36
- 230000004913 activation Effects 0.000 claims description 30
- 210000004881 tumor cell Anatomy 0.000 claims description 18
- 210000001616 monocyte Anatomy 0.000 claims description 16
- 230000011664 signaling Effects 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 230000001086 cytosolic effect Effects 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 239000000411 inducer Substances 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 210000003370 receptor cell Anatomy 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 3
- 230000005012 migration Effects 0.000 claims description 3
- 238000013508 migration Methods 0.000 claims description 3
- 101100231743 Homo sapiens HPRT1 gene Proteins 0.000 claims description 2
- 108091006088 activator proteins Proteins 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 69
- 108090000623 proteins and genes Proteins 0.000 description 28
- 230000010287 polarization Effects 0.000 description 24
- 102000004127 Cytokines Human genes 0.000 description 23
- 108090000695 Cytokines Proteins 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 18
- 210000003690 classically activated macrophage Anatomy 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 230000033115 angiogenesis Effects 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 230000004614 tumor growth Effects 0.000 description 14
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 13
- 206010027476 Metastases Diseases 0.000 description 13
- 230000009401 metastasis Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 12
- 238000009169 immunotherapy Methods 0.000 description 12
- 210000004322 M2 macrophage Anatomy 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 229940122361 Bisphosphonate Drugs 0.000 description 10
- 102000003814 Interleukin-10 Human genes 0.000 description 10
- 108090000174 Interleukin-10 Proteins 0.000 description 10
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 10
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 102000013462 Interleukin-12 Human genes 0.000 description 9
- 108010065805 Interleukin-12 Proteins 0.000 description 9
- 108091008874 T cell receptors Proteins 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 150000004663 bisphosphonates Chemical class 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 239000002679 microRNA Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000002619 cancer immunotherapy Methods 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000000770 proinflammatory effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 101800000628 PDH precursor-related peptide Proteins 0.000 description 6
- 101710094705 Sedoheptulokinase Proteins 0.000 description 6
- 102100029990 Sedoheptulokinase Human genes 0.000 description 6
- 230000002491 angiogenic effect Effects 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 5
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 5
- -1 CCL3 Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000037353 metabolic pathway Effects 0.000 description 5
- 108091070501 miRNA Proteins 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000005751 tumor progression Effects 0.000 description 5
- 102000006306 Antigen Receptors Human genes 0.000 description 4
- 108010083359 Antigen Receptors Proteins 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 230000010190 G1 phase Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 4
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 4
- 108010042237 Methionine Enkephalin Proteins 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 4
- 101100165729 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) stk-1 gene Proteins 0.000 description 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 206010052015 cytokine release syndrome Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 2
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 2
- 102100021723 Arginase-1 Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010050685 Cytokine storm Diseases 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 2
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 2
- 102000014736 Notch Human genes 0.000 description 2
- 108010070047 Notch Receptors Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 101150045355 akt1 gene Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000004108 pentose phosphate pathway Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108010078070 scavenger receptors Proteins 0.000 description 2
- 102000014452 scavenger receptors Human genes 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BFFPVEVGHKMWLT-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurin-6-one Chemical compound O=C1NC=NC2=C1NC=N2.O=C1NC(N)=NC2=C1NC=N2 BFFPVEVGHKMWLT-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 101150107888 AKT2 gene Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 101710129000 Arginase-1 Proteins 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 238000011523 CAR-T cell immunotherapy Methods 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 1
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 1
- 101000800463 Homo sapiens Transketolase Proteins 0.000 description 1
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108091007772 MIRLET7C Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101150100944 Nos2 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 101150043341 Socs3 gene Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 108700026078 glutathione trisulfide Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 108091005453 macrophage Toll-like receptors Proteins 0.000 description 1
- 108091005446 macrophage receptors Proteins 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013606 secretion vector Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240528P | 2015-10-13 | 2015-10-13 | |
| US62/240,528 | 2015-10-13 | ||
| US201615236421A | 2016-08-13 | 2016-08-13 | |
| US15/236,421 | 2016-08-13 | ||
| PCT/IB2016/056140 WO2017025944A2 (fr) | 2015-08-13 | 2016-10-13 | Car macrophage (moto-car) en immunothérapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180054600A true KR20180054600A (ko) | 2018-05-24 |
Family
ID=62299116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187007097A KR20180054600A (ko) | 2015-10-13 | 2016-10-13 | 면역치료에서의 대식세포 키메라 항원 수용체(moto-car) |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3334764A2 (fr) |
| KR (1) | KR20180054600A (fr) |
| CN (1) | CN108137704A (fr) |
| WO (1) | WO2017025944A2 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022186625A1 (fr) * | 2021-03-03 | 2022-09-09 | 서울대학교산학협력단 | Procédé de production de macrophages à récepteur chimérique à l'antigène et utilisation de telles cellules |
| KR20220131801A (ko) | 2021-03-22 | 2022-09-29 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR20220132401A (ko) | 2021-03-23 | 2022-09-30 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US10434153B1 (en) | 2015-05-20 | 2019-10-08 | Kim Leslie O'Neill | Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors |
| MX2018001182A (es) | 2015-07-28 | 2018-04-20 | Univ Pennsylvania | Monocitos/macrofagos modificados que expresan receptores de antigeno quimerico y sus usos. |
| US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| JP2019536471A (ja) | 2016-09-27 | 2019-12-19 | セロ・セラピューティクス・インコーポレイテッドＣＥＲＯ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | キメラエンガルフメント受容体分子 |
| CA3062978A1 (fr) * | 2017-05-17 | 2018-11-22 | Thunder Biotech Inc. | Macrophages transgeniques, recepteurs d'antigenes chimeriques et methodes associees |
| US10415017B2 (en) | 2017-05-17 | 2019-09-17 | Thunder Biotech, Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
| AU2018341244A1 (en) | 2017-09-26 | 2020-03-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
| CA3106796A1 (fr) * | 2018-07-19 | 2020-01-23 | Oncohost Ltd | Il-31 ameliorant l'efficacite d'une therapie cellulaire adoptive a base de macrophages contre le cancer |
| CN110872354B (zh) * | 2018-09-04 | 2022-11-01 | 华瑞同康生物技术（深圳）有限公司 | 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用 |
| JP6935383B2 (ja) * | 2018-09-27 | 2021-09-15 | 公益財団法人実験動物中央研究所 | 免疫不全マウス |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| WO2020176605A1 (fr) * | 2019-02-26 | 2020-09-03 | The University Of Vermont And State Agricultural College | Anticorps anti-néoantigènes et leurs utilisations |
| JP2022531325A (ja) * | 2019-04-30 | 2022-07-06 | マイエロイド・セラピューティクス，インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびそれらの使用の方法 |
| WO2021046243A2 (fr) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Méthodes et compositions d'intégration génomique |
| WO2021119538A1 (fr) * | 2019-12-11 | 2021-06-17 | Myeloid Therapeutics, Inc. | Compositions de cellules thérapeutiques et procédés de production et méthodes d'utilisation associés |
| WO2021248061A1 (fr) | 2020-06-04 | 2021-12-09 | Carisma Therapeutics Inc. | Nouvelles constructions pour récepteurs antigéniques chimériques |
| CN111925448B (zh) * | 2020-08-03 | 2022-06-21 | 山东大学 | 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用 |
| JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス，インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
| EP4346912A1 (fr) * | 2021-05-25 | 2024-04-10 | Institut Curie | Cellules myéloïdes surexprimant bcl2 |
| CN115011561A (zh) * | 2022-06-22 | 2022-09-06 | 深圳先进技术研究院 | 一种嵌合抗原受体巨噬细胞及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0785993B1 (fr) | 1993-08-06 | 2003-05-07 | Brigham Young University Technology Transfer Office | Anticorps monoclonaux des isozymes de type thymidine kinase |
| US7311906B2 (en) | 2004-04-30 | 2007-12-25 | Brigham Young University | Anti-viral activity of an anti-thymidine kinase monoclonal antibody |
| US7837998B2 (en) | 2004-05-21 | 2010-11-23 | Nathaniel Lallatin | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
| US20100143290A1 (en) * | 2008-12-04 | 2010-06-10 | Lallatin Nathaniel C | Monoclonal antibodies to human thymidine kinase to treat cancer |
| WO2011082345A2 (fr) * | 2009-12-30 | 2011-07-07 | Brigham Young University | Compositions et procédés de gestion du cancer à l'aide d'anticorps de liaison aux enzymes des voies de récupération nucléotidique et à leurs complexes |
| WO2015063069A1 (fr) * | 2013-10-28 | 2015-05-07 | Benjamin Felder | Récepteurs antigéniques chimériques avec domaines de liaison à l'antigène dérivés des récepteurs des cellules t gamma delta |
| CN104910279B (zh) * | 2015-06-05 | 2019-02-22 | 重庆精准生物技术有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
-
2016
- 2016-10-13 EP EP16801306.8A patent/EP3334764A2/fr not_active Ceased
- 2016-10-13 KR KR1020187007097A patent/KR20180054600A/ko not_active Application Discontinuation
- 2016-10-13 CN CN201680059778.7A patent/CN108137704A/zh active Pending
- 2016-10-13 WO PCT/IB2016/056140 patent/WO2017025944A2/fr active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022186625A1 (fr) * | 2021-03-03 | 2022-09-09 | 서울대학교산학협력단 | Procédé de production de macrophages à récepteur chimérique à l'antigène et utilisation de telles cellules |
| KR20220131801A (ko) | 2021-03-22 | 2022-09-29 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR20220132401A (ko) | 2021-03-23 | 2022-09-30 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3334764A2 (fr) | 2018-06-20 |
| WO2017025944A2 (fr) | 2017-02-16 |
| WO2017025944A3 (fr) | 2017-04-27 |
| CN108137704A (zh) | 2018-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180054600A (ko) | 면역치료에서의 대식세포 키메라 항원 수용체(moto-car) | |
| US11352439B2 (en) | Macrophage CAR (MOTO-CAR) in immunotherapy | |
| KR102624509B1 (ko) | 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주 | |
| US20240093178A1 (en) | Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy | |
| JP2021040648A (ja) | 腫瘍細胞による免疫抑制を低下させるための方法および組成物 | |
| EP3695408A1 (fr) | Procédés et compositions pour détecter et moduler une signature génétique de résistance à l'immunothérapie dans un cancer | |
| Soldevilla et al. | 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia | |
| EP3606518A1 (fr) | Méthodes et compositions de détection et de modulation d'une signature génique de résistance à l'immunothérapie d'un cancer | |
| WO2018067991A1 (fr) | Modulation de nouvelles cibles de points de contrôle immunitaires | |
| WO2016038550A1 (fr) | Inhibition de prmt5 dans le traitement de maladies liées à une déficience en mtap | |
| WO2019094955A1 (fr) | Méthodes et compositions pour cibler des programmes oncogènes et de développement dans les gliomes h3k27m | |
| KR20220147109A (ko) | 키메라 항원 수용체 발현 세포의 제조 방법 | |
| CN112512533A (zh) | 用于治疗癌症的材料与方法 | |
| US11098283B2 (en) | T cells modified to overexpress c-Myb | |
| EP2734237A2 (fr) | Modulation de chimiokines de manière sélective vis-à-vis de tumeurs | |
| JP2023529460A (ja) | 免疫応答を増強するための組成物および方法 | |
| JPWO2020150478A5 (fr) | ||
| US20220372170A1 (en) | Macrophage CAR (MOTO-CAR) In Immunotherapy | |
| AU2016305353B2 (en) | Macrophage chimeric antigen receptor (MOTO-CAR) in imunotherapy | |
| EP4188954A1 (fr) | Cellules car-t doubles | |
| JP2022524994A (ja) | Ｔ細胞受容体及びその使用方法 | |
| JP2022523552A (ja) | Ｔ細胞受容体及びその使用方法 | |
| US20210069245A1 (en) | Mirna modulation of t cell signaling and uses thereof | |
| TW202325842A (zh) | 培養表現ｒｏｒ１結合蛋白之細胞之方法 | |
| Weinstein | Il-36 Gamma Promotes Anti-Tumor Immunity Through Therapeutic Induction of Tumor-Associated Tertiary Lymphoid Structures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |